@article{article_1697699, title={Synthesis of 7-(3-(4-(2,3-dichlorophenyl)piperazin-1-yl)propoxy)-3,4-dihydroquinolin-2(1H)-one and Screening Its Cholinesterase Inhibitor Properties}, journal={EMU Journal of Pharmaceutical Sciences}, volume={8}, pages={8–13}, year={2025}, DOI={10.54994/emujpharmsci.1697699}, author={Dehnabi, Manijeh and Mavideniz, Açelya and Ercetin, Tugba and Gülcan, Hayrettin Ozan}, keywords={Alzheimer’s disease, Antioxidant activity, Aripiprazole, Cholinesterase inhibition, Modified Ellman’s method}, abstract={Aripiprazole is a well-known atypical antipsychotic drug [i.e., 7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one]. The pharmacological effects of aripiprazole are primarily attributed to its partial agonist activity at dopamine and serotonin receptors, although the exact mechanism of action remains unclear. However, it is generally accepted that aripiprazole exerts its therapeutic effects by modulating dopaminergic and serotoninergic neurotransmission. This study aimed to synthesize a modified derivative of aripiprazole and to investigate the cholinesterase inhibitory potential of this compound. The cholinesterase inhibition potential of the synthesized compound was evaluated using the Ellman’s method. The inhibitory activities against various cholinesterases were determined. The results indicated that the scaffold employed might be used for further cholinesterase inhibitor molecule design.}, number={1}, publisher={Dogu Akdeniz University}